Semaglutide Injectable Suppliers & Bulk Manufacturers
Available Forms: Injection(SQ)
Available Strengths: 0,25 mg - 2.4 mg per injection for weight management
Reference Brands: Wegovy(US & EU)
Category:
Weight Loss drugs
Wegovy (semaglutide 2.4 mg) is a GLP-1 receptor agonist that mimics natural hormones to increase insulin secretion, suppress appetite, and slow gastric emptying. It supports weight loss, improves metabolic health, reduces hunger, and helps manage obesity, promoting long-term weight reduction and overall wellness.
Semaglutide Injectable is available in Injection(SQ)
and strengths such as 0,25 mg - 2.4 mg per injection for weight management.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Semaglutide Injectable is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Semaglutide Injectable can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Wegovy (semaglutide 2.4 mg) injection is approved in the US by the FDA and in the EU via EMA for chronic weight management. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews clinical trial and quality data for timely approval, while the EMA ensures regional safety and manufacturing compliance. For dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence supports swift approval, safe administration, and global availability, helping patients worldwide achieve significant weight loss and improved metabolic health through high-quality, long-acting GLP-1 receptor agonist therapies.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing